Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Though metastatic breast cancer survival is improving, rates vary by region

Key clinical point: Geographic location, age, and race all contribute to variance in metastatic breast cancer survival rates.

Major finding: Patients in the individual cohort from the Seattle-Puget Sound region had 5-year BCSS rates that improved from 29% in 1990-1998 (95% CI, 18%-37%; P less than .001) to 56% in 2005-2011 (95% CI, 45%-65%; P = .004).

Study details: A comparative analysis of patients diagnosed with a first primary, de novo, stage IV breast cancer at ages 25-84 years from 1990 to 2011.

Disclosures: The study was funded by the Kaplan Cancer Research Fund, the Metastatic Breast Cancer Alliance, and the Surveillance, Epidemiology, and End Results Cancer Surveillance System program of the National Cancer Institute. The authors report no conflicts of interest.

Citation:

Malmgren JA et al. Cancer. 2019 Oct 22. doi: 10.1002/cncr.32531.